Illumina, Inc. $ILMN Shares Sold by Aberdeen Group plc

Aberdeen Group plc cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 50.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 117,085 shares of the life sciences company’s stock after selling 117,309 shares during the period. Aberdeen Group plc owned about 0.08% of Illumina worth $15,357,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Board of the Pension Protection Fund acquired a new stake in shares of Illumina during the fourth quarter valued at about $26,000. Quent Capital LLC acquired a new position in Illumina in the third quarter worth about $29,000. Quarry LP acquired a new position in Illumina in the third quarter worth about $32,000. Aster Capital Management DIFC Ltd acquired a new position in Illumina in the third quarter worth about $33,000. Finally, Strategic Advocates LLC acquired a new position in Illumina in the third quarter worth about $44,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on ILMN. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. UBS Group reissued a “neutral” rating and issued a $135.00 target price on shares of Illumina in a report on Friday, February 6th. Wall Street Zen raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Barclays raised their target price on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Finally, JPMorgan Chase & Co. cut their target price on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and a consensus target price of $129.69.

Insider Activity

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 2.60% of the stock is owned by company insiders.

Illumina Trading Up 0.3%

NASDAQ ILMN opened at $127.74 on Tuesday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The stock has a market cap of $19.53 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 2.44 and a beta of 1.49. The firm’s 50 day moving average price is $125.90 and its two-hundred day moving average price is $122.94.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.